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Recent reports point out the importance of the complex GK-GKRP in controlling glucose and lipid homeostasis. Several GK
mutations aﬀect GKRP binding, resulting in permanent activation of the enzyme. We hypothesize that hepatic overexpression
of a mutated form of GK, GKA456V, described in a patient with persistent hyperinsulinemic hypoglycemia of infancy (PHHI)
and could provide a model to study the consequences of GK-GKRP deregulation in vivo. GKA456V was overexpressed in the liver
of streptozotocin diabetic mice. Metabolite profiling in serum and liver extracts, together with changes in key components of
glucose and lipid homeostasis, were analyzed and compared to GK wild-type transfected livers. Cell compartmentalization of the
mutant but not the wild-type GK was clearly aﬀected in vivo, demonstrating impaired GKRP regulation. GKA456V overexpression
markedly reduced blood glucose in the absence of dyslipidemia, in contrast to wild-type GK-overexpressing mice. Evidence in
glucose utilization did not correlate with increased glycogen nor lactate levels in the liver. PEPCKmRNA was not aﬀected, whereas
the mRNA for the catalytic subunit of glucose-6-phosphatase was upregulated ∼4 folds in the liver of GKA456V-treated animals,
suggesting that glucose cycling was stimulated. Our results provide new insights into the complex GK regulatory network and
validate liver-specific GK activation as a strategy for diabetes therapy.
1. Introduction
Glucokinase (GK) (EC 2.7.1.1) is expressed in glucosensitive
cells of the pancreas, liver, hypothalamus, anterior pituitary
gland, and enteroendocrine K and L cells [1–3]. GK has a
prominent role as a glucose sensor because of its specific
kinetic properties, including an aﬃnity for glucose that is
within the physiological plasma concentration range (half-
saturation level for glucose [S0.5] of ∼8mmol/L), positive
cooperativity, and lack of inhibition by glucose-6-phosphate.
In liver and brain, GK is controlled by an endogenous
inhibitor, the glucokinase regulatory protein (GKRP) [4, 5].
During starvation, the enzyme is bound to GKRP, leading
to its inactivation and sequestration in the nucleus. After
refeeding, glucosemediates the dissociation of the GK-GKRP
complex and GK translocates to the cytoplasm. Also, several
naturally occurring activatingmutations have been described
that induce a conformational change in GK, which results
in higher aﬃnity for glucose, and reduce the interaction
between GK and GKRP [6, 7]. One such mutation, A456V,
completely impairs GK-GKRP complex. Similarly, synthetic
GK activators (GKAs) enhance GK activity and induce its
translocation to the cytosol. [8–12].
There is evidence that a defect in GKRP regulation of GK,
resulting in increased liver GK activity probably as a result
of increased cytosolic translocation, has consequences on
glucose and triglyceride homeostasis in humans, even though
these patients have reduced risk to type 2 diabetes [13, 14].
We aimed to study the metabolic consequences of
GK-GKRP deregulation by overexpressing a GK activating
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mutant (GKA456V) in the liver of insulin-deficient mice (lack-
ing endogenous GK). Transfected GK456V is maintained in
the cytosol of hepatocytes in vivo leading to improved glyce-
mia in the absence of dyslipidemia. These data provide novel
insights into the consequences of GK-GKRP derangement
and widen the scope for GKA research in the liver.
2. Materials andMethods
2.1. Directed Mutagenesis. The cDNA Encoding Rat GK Was
Kindly Provided by Dr. Fatima Bosch (CBATEG, Univer-
sitat Auto`noma de Barcelona). Site-Directed Mutagenesis
to Generate GK-A456V cDNA Was Performed Using the
QuickChange Site-Directed Mutagenesis Kit (Strategene),
and Specific Primers Containing the Desired Mutation (3′C-
TGGTCTCTGCGGCGGCCTGCAAGAAG5′ and 5′GACCA-
GAGACGCCGCCGGTGCAAGAACG3′) from Dharmacon.
Successful Incorporation of the Mutation Was Confirmed by
DNA Sequence Analyses.
2.2. Plasmid Construction and Kinetic Analysis of Expressed
GKs. The cDNAs for GK and GK-A456V were cloned into
EcoRI-BglII of a pCAGGs vector which contains the CAG (cy-
tomegalovirus immediate-early enhancer-chicken β-actin
hybrid) promoter [15]. The resulting plasmids pGK and
pGKA456V were amplified in E. coli JM109 cells and extracted
using NucleoBond PC 2000 EF Mega Prep kit (Macherey-
Nagel). DNA for animal injection was digested with SalI
and HindIII which cut on both sides of the expression
cassette [16, 17] in order to extend expression in vivo. Later,
DNA was purified by phenol/chloroform extraction. Ex-
pression plasmids were transfected in HuH7 cells for
kinetic analysis (Supplementary Figure 1 available at doi:
10.1155/2011/707928).
2.3. Animal Care and Treatment. Male ICR mice purchased
from Harlan Interfarma IBERICA S.L were maintained in
a constant 12-hour light-dark cycle and fed standard ro-
dent chow and water ad libitum. All animal protocols were
approved by the Ethics Committee at the University of
Barcelona. To obtain diabetic animals, mice weighing ap-
proximately 22 g were injected i.p. with a single dose
of streptozotocin (STZ) (200mg/kg) dissolved in 100mM
citric/citrate buﬀer, pH 4.5. One week later, glycemia was
assessed after a 5-hour fast. Only those mice that had
glycemia over 350mg/dL were used. Digested plasmid DNA
was introduced into murine livers using a hydrodynamic-
based gene transfer technique via rapid injection of a large
volume of DNA solution through the tail vein [18]. Briefly,
60 μg/mouse DNA was diluted in 2.0 to 2.5mL of apyrogenic
Ringer-lactate solution (Fresenius Kabi) (0.1mL/g body
weight) and injected into the tail vein using a 27-gauge
needle and syringe within 5 to 10 seconds. Typically, the
mice recovered from the injection within 2 to 10min. At
the end of the experiment, animals were sacrificed under
xylazine/ketamine anesthesia. Blood samples were taken
by inferior cava vein puncture and serum was obtained
by centrifugation at 700×g at 4◦C for 15min. Liver was
dissected, snap frozen in liquid nitrogen, and subsequently
stored at −80◦C until analysis.
2.4. Immunohistochemistry. For GK immunodetection, livers
from 5-hour fasted animals were fixed in a 4% PFA solution
and frozen in OCT compound. 7 μm cryosections were obt-
ained in a cryostat and immunostained with a 1 : 50 dilu-tion
of GK antibody (AP7901c, Abgen) followed by an anti-rabbit
antibody Alexa Fluor 488 (Molecular Probes).
2.5. Blood Metabolite Assays. Blood glucose levels were mea-
sured using a Glucocard Memory 2 apparatus (Menarini)
from a blood drop collected from the tail tip. The Veterinar-
ian Clinical Biochemistry Service from the Veterinary Hos-
pital of the Universitat Auto`noma de Barcelona, Bellaterra,
Spain, measured serum metabolites. Serum insulin was de-
termined using Ultrasensitive Mouse Insulin ELISA (Merco-
dia AB).
2.6. RNA Extraction and Quantitative. RT-PCR Total RNA
was extracted with RNAeasy mini kit (Quiagen). cDNA
synthesis was performed using Ready-To-Go You-Prime First
Strand Beads (Amersham Biosciences) with random hexam-
ers. mRNA levels of the transgenic rat GK (r-GK) were quan-
tified with specie-specific primers (Applied Biosystems) and
normalized using β-2-microglobulin as an internal control
in an HT7700 Real Time-PCR system (Applied Biosystems).
Data analysis was based on the ΔΔCt method (Applied Bios-
ystems).
mRNA levels of selected genes of interest were measured
running a Low Density Array (Applied Biosystems) in an
HT7900 Real Time-PCR system (Applied Biosystems). Ex-
pression was normalized using β-2-microglobulin as an en-
dogenous control. Data analysis followed the ΔΔCt method.
2.7. GK Activity. Frozen liver samples were homogenized in
ice-cold homogenization buﬀer (HEPES 50mM pH 7.4, KCl
100mM, EDTA 1mM, MgCl2 5mM, DTT 2.5mM) using
a polytron PT 3000 and centrifuged at 100,000×g for 1
hour at 4◦C. Supernatants were used for the determination
of GK activity following the spectrophotometric method
described by Davidson and Arion [19]. Briefly, the assays
were carried out in a solution containing HEPES 50mM pH
7.4, KCl 100mM, MgCl2 7.5mM, NAD+ 1mM, ATP 5mM,
BSA 1% and indicated amounts of glucose. The reactions
were initiated by adding 5U/mL of glucose-6-phosphate
dehydrogenase (G6PDH) from Leuconostoc mesenteroides
(Roche) and the rate of increase in absorbance at 340 nm was
measured. The GK activity was calculated as the diﬀerence
between the kinase activities measured at diﬀerent glucose
concentrations and 0.5mM glucose (hexokinase activity),
and was expressed as mUnits/mg liver.
2.8. G6PDH Activity. Frozen liver samples were homoge-
nized in ice-cold buﬀer, which contained HEPES 50mM pH
7.4, KCl 100mM, EDTA 1mM, MgCl2 5mM, DTT 2.5mM,
and 1% pluronic F-127 (Calbiochem), and centrifuged at
20,000×g for 20min at 4◦C. G6PDH activity was assayed
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Figure 1: Rat GK and GKA456V overexpression in the livers of STZ-treated mice. 60 μg of pControl, pGK, or pGKA456V were
hydrodynamically-transfected to diabetic mice. (a) GK protein content of liver homogenates was determined by Western blot. A
representative blot and densitometric analysis is shown. (b) Further confirmation of GK overexpression was obtained by analysis of specific
GK activity in liver extracts at diﬀerent glucose concentration. Values are expressed as the means ± SE (N = 4. ∗P < 0.05 versus pControl).
by measuring the rate of NADPH production from NADP+
0.5mM and glucose-6-phosphate 2mM, at pH 7.6 [20].
Results were expressed as mUnits/mg protein in the super-
natant. Protein was measured using the Bradford method
(Bio-Rad).
2.9. Western Blot. Frozen tissue was homogenized in radio-
immunoprecipitation assay buﬀer (RIPA) supplemented
with protease and phosphatase inhibitors and centrifuged
at 15,000×g for 15min at 4◦C. 30 μg of tissue extract was
resolved by SDS-PAGE (8–12% gel) and electrotransferred
onto a Hybond-P membrane (Amersham Biosciences). Anti-
body against GK (H-88, Sta Cruz) was used at 1/500 dilution.
1/1000 dilution was used for the following antibodies:
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (ub-
PFK2) and L-pyruvate kinase (L-PK) (gifts from Ramon Bar-
trons, Barcelona University), and Carbohydrate Response
Element Binding Protein (CHREBP) (Novus Biologicals).
ACC and ACC-P Ser-79 (Upstate) were used at 1/2000.
Sheep anti-PEPCK-C antiserum (a gift from Daryl Granner,
Vandervilt University, USA) was used at 1 : 20,000 dilution.
All membranes were normalized using monoclonal anti-γ-
tubulin (Sigma) at 1 : 10,000 dilution. Horseradish peroxi-
dase activity linked to secondary antibody was detected with
ECL substrate (Pierce) in a Fujifilm LAS 300 Intelligent Dark
Box IV imaging system. Densitometry was performed using
Multi Gauge Software.
2.10. Hepatic Metabolites. To measure hepatic free glucose,
glucose-6-phosphate (G6P), and lactate, acid homogenates
were obtained from frozen liver. Briefly, perchloric acid 10%
was added to frozen pieces of liver (5 : 1 v : w) and the
mixture was homogenized in a Potter Elvehjem apparatus
at 1,500 rpm. The homogenate was then centrifuged at
20,000×g for 10min at 4◦C. The supernatant was brought
to pH 7 with K2CO3 4N and centrifuged again to remove the
KClO4 formed during neutralization. Free glucose was mea-
sured using a Glucose Oxidase kit (Sigma). G6P was mea-
sured following the spectrofluorometric method described
by Lang & Michal, which is based in the reaction cat-
alyzed by G6PDH. Briefly, the assay solution contained tri-
ethanolamine 0.2M pH 7.6, NADP+ 0.2M, MgCl2 5mM,
and G6PDH 0.17U/mL. Lactate was determined by a spec-
trophotometric method based on the reaction catalyzed
by lactate dehydrogenase, following Gutmann & Wahlefeld.
Briefly, the reaction cuvette contained hydrazine/glycine
buﬀer 0.25M/0.7M, pH 9.3, EDTA 0.15mM, NAD+ 2mM,
and 35U/mL of lactate dehydrogenase.
For fructose-2,6-bisphosphatase (F2,6bP) determina-
tion, frozen livers were homogenized in 0.1M NaOH, heat-
ed to 80◦C for 15min, and centrifuged at 12,000×g for
5min. F2,6bP was determined in supernatants by its ability
to activate pyrophosphate-dependent 6-phosphofructo-1-
kinase from potato tubers, as described by Van Schaftingen
et al. [21].
The hepatic triacylglyceride (TAG) content wasmeasured
in 3M KOH, 65% ethanol extracts using a TAG kit (Sigma),
based on the method of Salmon and Flatt for liver saponifi-
cation.
Hepatic glycogen content was measured essentially as
described elsewhere [22].
2.11. Whole-Body Glucose Utilization. A solution of U-14C-
glucose and glucose was intraperitoneally injected into 5-
hour fasted STZ-diabetic mice (0.2mg glucose, 10 μCi per
animal). Blood, liver, brain, and muscle were obtained 30
minutes after injection and dissolved into Solvable (Perkin
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Figure 2: GK and GKA456V localization inside hepatocytes. Liver sections of 5-hour fasted mice injected with pControl, pGK, or pGKA456V
were immunostained with GK antibody. TO-PRO-3 was used to visualize nuclei7.5.
Elmer). Blood samples were bleached with EDTA 0.1M and
H2O2 (30%), and liver and brain samples were bleached with
H2O2 (30%) alone. Radioactivity was quantified by adding
scintillation liquid (Ecoscint H) and counted in a Wallac
1409-001 counter.
2.12. Statistical Analysis. Results are expressed as the mean
± standard error (SE). Statistical analysis was performed by
one-way ANOVA with Bonferroni posttest. Diﬀerences were
considered significant when P < 0.05.
3. Results
3.1. Liver Overxpression of pGK and pGKA456V. pGKA456V,
wild-type GK (pGK) and an empty vector (pControl), were
introduced into the liver of streptozotocin (STZ-) treated
mice. Hydrodynamic-based delivery of plasmid DNA led to
specific transfection of hepatocytes around the central vein
[23, 24], reproducing the physiologic distribution of GK
in the liver acinus [25]. This technique induces a transient
release of liver enzymes that returns to control values by
the second day after injection. Consistently, transaminase
levels were low at the end-point of analysis, and similar in all
treat-ment groups (pControl 207.5 ± 29.88U/L, pGK 121.0
± 48.43U/L, pGKA456V 117.5 ± 40.35U/L; n = 4–9).
At the time of injection mice were hyperglycemic
(>350mg/dL) and their insulin level was undetectable
(<0.1 μg/L). Forty-eight hours postinjection the expression
of transfected rat GK and GKA456V was detected by RT-
PCR (data not shown). Further confirmation of GK over-
expression was obtained by Western blot from liver extracts
(Figure 1(a)) and GK activity assay (Figure 1(b)). GK activity
was undetectable in pControl transfected livers irrespective
of glucose concentration, as expected in long-term STZ
diabetic animals. In contrast, both pGK and pGKA456V
transfected groups had similar GK activity at 100mM
glucose (mU/g fresh), demonstrating that both treatment
groups had similar amounts of GK protein. Consistent
with the S0.5 for glucose of GKA456V, liver extracts from
pGKA456V-injected animals had twice the GK activity of
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Figure 3: Blood glucose homeostasis in GK- and GKA456V-treated
mice. Streptozotocin-induced diabetic mice were hydrodynamically
injected with of pControl, pGK or pGKA456V. (a) Blood glucose
levels were determined 48 h posttransfection in fed state and after
a 5-hour fast. Values are the mean ± SE (N = 5–12, ∗P < 0.05
versus pControl, §P < 0.05 versus pControl and versus pGK). (b)
Glucose tolerance test in overnight fasted, healthy mice transfected
with pControl, pGK, or pGKA456V. ∗∗AUC versus pControl and
pGK.
livers from pGK-injected animals at physiological glucose
concentrations (5mM) (Figure 1(b)) .
3.2. Diﬀerent Compartmentalization of GK and GKA456V.
GKRP retains GK in the nucleus at low glucose concentra-
tions and releases GKwhen insulin, high glucose, or fructose-
1P are present [26, 27]. Diﬀerent studies have suggested that
the A456V mutation impairs GKRP regulation in vitro [6,
28]. Therefore, we assessed GKRP-dependent nuclear seques-
tration in primary hepatocytes from STZ-treated rats trans-
fected with pGK and pGKA456V, in the presence or absence of
pGKRP. Densitometry analysis ofWestern blots from nuclear
and cytosolic fractions showed that cellular GKA456V distri-
bution was not aﬀected by the presence of GKRP (data not
shown). We next examined the compartmentalization of GK
and GKA456V in vivo by immunohistochemistry. pGK-treated
mice showed GK immunoreactivity throughout the liver,
especially in nuclei (Figure 2). Interestingly, overexpressed
GKA456V protein was localized predominantly in the cytosol
of transfected hepatocytes. These data demonstrates, that im-
paired GKRP binding to GKA456V changes its compartmen-
talization in vivo.
3.3. Glucose Homeostasis in Fed Animals. The impact of
both GK enzymes on glucose metabolism was first evaluated
in fed animals. Both GK and GKA456V slightly reduced
glycemia (Figure 3(a)). To explore the fate of glucose in the
liver, we measured several metabolites in hepatic extracts
(Table 1). Fed pGK-treated mice showed significantly higher
F2,6BP and glycogen contents (Figure 4(a)), together with a
rise in lactate, indicating a higher glycolytic flux. GKA456V-
expressing livers also showed higher hepatic free glucose than
both control and GK groups, even though the content of G6P
was similar in all three groups. Furthermore, both F2,6BP
and lactate content were increased. Glycogen content was
significantly higher than control but similar to pGK-treated
group (Figure 4(a)).
3.4. Glucose Homeostasis in 5-Hour Fasted Animals.
pGKA456V-treated animals showed a marked reduction of
glycemia after a 5-hour fast (Figure 3(a)). Lactate was only
increased after pGK treatment (pControl, 7.296± 0.772mM;
pGKA456V, 8.778 ± 0.649mM; pGK, 10.62 ± 0.608mM—
P < 0.05 versus pControl and pGKA456V—). Hepatic free
glucose content was low in the pGKA456V treatment group
(Table 1). G6P levels were reduced to the same extent
in control and GKA456V groups, whereas GK-expressing
animals showed similar G6P and ATP concentrations to
well-fed animals. F2,6BP and lactate levels remained higher
in both treatment groups as compared to control. Glycogen
content in GK-expressing animals was significantly higher
than control and GKA456V-expressing groups. Fed-to-fast
transition produced a marked reduction of glycogen stores
in pGKA456V-treated animals as compared to pControl
and pGK, suggesting an increased rate of glycogenolysis
in GKA456V-expressing animals (Figure 4(b)). In order to
clarify whether glucose distribution in vivo favored the liver,
we quantitated 14C radioactivity derived from uptake and
metabolism of U14C-glucose in various tissues 30 minutes
after injection. 14C label was increased exclusively in the liver
of both pGK and pGKA456V treatment groups (control, 100
± 7.88%; GK, 138.73 ± 14.63%; GKA456V 144.1 ± 8.99%;
P = 0.037 GK versus control and P = 0.003 pGKA456V versus
control). To assess whether pGKA456V expression would
aﬀect glucose clearance in healthy mice, we performed a
glucose tolerance test 1 week after transfection (Figure 3(b)).
Liver GK overexpression has been associated with dislipi-
demia [29]. Consistently, our data demonstrates a significant
increase in serum TAG (pControl 33.5 ± 7.72mg/dL,
pGKA456V 38.13 ± 7.66mg/dL, pGK 74.00 ± 14.76mg/dL,
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Table 1: Liver metabolites of STZ-diabetic mice transfected with pControl, pGK and pGKA456V.
Fed 5 h-Fasted
pControl pGK pGKA456V pControl pGK pGKA456V
Glc (μmol/g liver)
40.70 ± 5.921 32.72 ± 1.475 47.68 ± 7.328 52.29 ± 9.524 32.23 ± 12.18 6.35 ± 4.043∗
n = 11 n = 6 n = 9 n = 5 n = 4 n = 4
G6P (μmol/g liver)
0.16 ± 0.021 0.14 ± 0.018 0.15 ± 0.021 0.06 ± 0.024 0.20 ± 0.068§ 0.04 ± 0.017
n = 11 n = 8 n = 10 n = 5 n = 4 n = 5
F2,6BP (nmol/g liver)
1.19 ± 0.215 2.84 ± 0.625∗ 1.90 ± 0.517 0.71 ± 0.173 9.86 ± 1.812§ 4.14 ± 1.607
n = 11 n = 8 n = 10 n = 5 n = 5 n = 5
Lactate (μmol/g liver)
1.31 ± 0.275 1.78 ± 0.424 2.27 ± 0.951 1.16 ± 0.239 1.28 ± 0.322 1.32 ± 0.222
n = 12 n = 8 n = 10 n = 5 n = 4 n = 5
TAG (mg/g liver)
6.25 ± 0.26 6.08 ± 0.36 6.26 ± 0.17 9.18 ± 1.48 12.56 ± 0.50 11.84 ± 2.13
n = 12 n = 8 n = 10 n = 5 n = 5 n = 5
GSH/GSSG ratio
11.73 ± 0.87 11.81 ± 0.93 11.37 ± 0.87 5.372 ± 0.49 9.479 ± 1.38 9.926 ± 1.84∗
n = 12 n = 8 n = 10 n = 5 n = 5 n = 5
Data are means ± SE. (N = 4–12). ∗P < 0.05 versus its pControl, §P < 0.05 versus fast pControl and fast pGKA456V.
45
30
15
0
G
ly
co
ge
n
(m
g
gl
c/
g
liv
er
)
Fed 5h-fasted
pControl pGK pGKA456V pControl pGK pGKA456V
∗∗
∗
∗
(a)
pControl pGK pGKA456V
G
ly
co
ge
n
(f
ed
-f
as
t
tr
an
si
ti
on
)
0
−10
−20
−30
−40
§
(b)
45
30
15
0
Fed 5h-fasted
pControl pGK pGKA456V pControl pGK pGKA456V
G
lc
6P
-D
H
ac
ti
vi
ty
(m
U
/m
g
pr
ot
)
(c)
pControl pGK pGKA456V
Δ
20
10
0
−10
−20
G
lc
6P
-D
H
ac
ti
vi
ty
(f
ed
-t
o-
fa
st
tr
an
si
ti
on
)
(d)
Figure 4: Eﬀects of GK and GKA456V overexpression on glycogen and glucose-6-phosphate DH activity in the liver. (a) Glycogen levels from
fed and 5-hour fasted mice. (b) Glycogen balance between the fast and fed transition. (c) Glc6P DH activity was measured in liver extracts of
mice in fed and fasted state. (d) Variation of Glc6P DH activity during the fed-to-fast transition. Data are mean ± SE. (N = 5–9. ∗P < 0.05
versus pControl; §P < 0.05 versus pControl and P < 0.01 versus pGK; ΔP < 0.05 versus pControl and pGK).
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Table 2: Gene expression profile in livers of diabetic mice after a short fast.
Gene Protein pControl pGK pGKA456V
Glycolysis and lipogenesis
Gck GK 1.26 ± 0.72 5.28 ± 1.49 1.73 ± 0.86
Pfkfb3 PFK2 1.05 ± 0.13 1.17 ± 0.19 1.22 ± 0.19
Nr1h3 Lxr-α 1.03 ± 0.11 0.81 ± 0.03 0.91 ± 0.05
Fasn FAS 1.14 ± 0.21 11.37 ± 5.76∗ 2.33 ± 0.42
Mod1 ME 1.05 ± 0.13 2.43 ± 0.91 1.57 ± 0.32
Myc c-myc 1.07 ± 0.26 3.29 ± 1.49 0.94 ± 0.19
Srebf1 SREBP1c 1.03 ± 0.10 0.90 ± 0.16 0.85 ± 0.11
Chrebp CHREBP 1.08 ± 0.12 2.31 ± 0.72 1.90 ± 0.29
Gluconeogenesis
Pck1 PEPCK-C 1.04 ± 0.12 0.52 ± 0.11∗ 0.91 ± 0.16
G6pc Glc-6Pase 0.95 ± 0.31 1.70 ± 0.56 4.52 ± 1.39§
Hnf4 HNF-4α 1.05 ± 0.13 0.68 ± 0.07 0.77 ± 0.12
Slc2a2 GLUT-2 1.01 ± 0.05 1.20 ± 0.25 1.01 ± 0.12
Energy metabolism
Cpt1a Cpt-1α 1.02 ± 0.09 0.83 ± 0.08∗ 0.92 ± 0.08
Hmgcs2 HmgCoA Synthase 1.02 ± 0.08 1.14 ± 0.22 0.91 ± 0.11
Mdh1 cMDH 1.01 ± 0.05 0.74 ± 0.04∗ 0.70 ± 0.10 ∗
Ucp2 UCP-2 1.03 ± 0.10 0.66 ± 0.02∗ 0.96 ± 0.15
Ppargc1 PGC-1α 1.02 ± 0.07 0.27 ± 0.07† 0.63 ± 0.14 ∗
Each value on the table represents the mean relative amount of mRNA with respect to that in the control experiment treatment (mean ± SE). Liver gene
expression profile was analyzed by qRT-PCR using Applied Biosystems 7900HT Micro Fluidic Card and ΔΔCt calculations. (N = 5 per group). ∗P < 0.05
versus pControl; §P < 0.05 versus pControl and pGK; †P < 0.001 versus pControl and P < 0.05 versus pGKA456V.
P < 0.05 versus pControl and pGKA456V) and NEFA
(pControl 0.325 ± 0.09mM, pGKA456V 0.4013 ± 0.05mM,
pGK 0.66 ± 0.10mM P < 0.05 versus pControl) only in
the postabsorptive state. Besides, GK overexpressing mice
showed a tendency to increase hepatic TAG content, which is
consistent with the literature [30, 31]. In contrast, GKA456V
overexpression did not promote dislipemia, as evidenced
by maintained levels of circulating NEFA and TAG. There
was a significant increase in β-hydroxybutyrate levels in
the pGKA456V group (pControl, 0.18 ± 0.03mM; pGKA456V,
0.27 ± 0.03mM—P < 0.05 versus pControl; pGK, 0.20 ±
0.01mM).
In order to elucidate the mechanism responsible for the
metabolic profile observed, we analyzed protein and mRNA
levels for key enzymes and transcription factors. Both GK
and GKA456V treatments were accompanied by increases in L-
PK protein (Figures 5(a) and 5(b)). pGK-treatment resulted
in higher levels of ubiquitous PFK2 (Pfkfb3) protein (Figures
5(a) and 5(b)), but not mRNA (Table 2), consistent with
elevated F2,6BP observed in this treatment group (Table 1).
Also, endogenous, mouse GKmRNA expression was induced
in the livers of pGK-injected mice, as detected by species-
specific qRT-PCR. Correlating with the induction of the
expression of endogenous GK, cMyc mRNA was only
increased in pGK-treated animals. Other regulatory factors
implicated in the regulation of endogenous GK expression,
such as SREBP and LXRα, were not aﬀected by treatment
with pGK and pGKA456V (Table 2).
As an increment in GK expression in the liver is
commonly associated with increased lipogenesis [32, 33],
enzymes and transcription factors involved in de novo lipo-
genesis were analyzed. GK- and pGKA456V-expressing groups
presented increased mRNA content for Fasn and Mod1 that
were more pronounced in pGK-treated animals. Also, Acc1
and Chrebp were more induced by the overexpression of GK
than by GKA456V.
GK, through the production of xylulose-5P, mediates the
inhibition of gluconeogenesis by glucose [34, 35]. F2,6BP
[36] has also been associated with the inhibitory eﬀect of
glucose metabolism on gluconeogenesis. Consistently, we
observed a reduction of PEPCK at the protein level in both
pGK- and pGKA456V-treated mice. However, PEPCK mRNA
was reduced only in GK-overexpressing animals. Similarly,
PGC-1α and HNF4α mRNAs were reduced in pGK-injected
mice, whereas GKA456V-overexpressing livers only showed
reduced PGC-1αmRNA.
In contrast, the level of mRNA for the catalytic subunit
of glucose-6-phosphatase (Glc6Pase) were strikingly higher
in GKA456V-overexpressing animals, consistent with more
glycogen breakdown observed after a 5-hour fast. Glc6Pase
protein was also increased as assessed by immunohistochem-
istry (Figure 5(c)). Similar results were observed in healthy
mice overexpressing pGKA456V after a short fast (data not
shown).
4. Discussion
To evaluate the consequences of GK activation and deregu-
lation by GKRP in the liver, we hydrodynamically injected
pGKA456V in the liver of STZ-diabetic mice. This strategy
8 International Journal of Endocrinology
1.5
1
0.5
0
50
0
2
1
0
1.5
1
0.5
0
1.2
0.9
0.6
0.3
0
∗
∗
∗
∗
∗
∗
L-
P
K
(r
el
at
iv
e
u
n
it
e)
A
C
C
.P
/A
C
C
(a
.u
.)
P
E
P
ck
(a
.u
.)
pControl pGK pGKA456V
pControl pGK pGKA456V
pControl pGK pGKA456V
pControl pGK pGKA456V
pControl pGK pGKA456V
10
20
30
40
C
h
R
E
B
P
(a
.u
.)
P
FK
2-
u
b
(a
.u
.)
(a)
PFK2-ub
L-PK
ChREBP
ACC-P
ACC
PEPck
pControl pGK pGKA456V
(b)
pControl pGK pGKA456V
(c)
Figure 5: Analysis of protein levels in livers transfected with GK and GKA456V. Livers excised from mice in postabsorptive state were
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allowed us to obtain a mouse model where the eﬀects
of exogenous GKs are isolated from those of endogenous
GK (undetectable levels of mouse GK mRNA and activity
in pControl-treated animals) and insulin action (insulin
levels <0.1 μg/L in all treatment groups). In addition, the
use of hydrodynamic gene transfer provides proper zonal
expression of GK and GKA456V in perivenous hepatocytes
[23, 25]. The eﬃciency of this gene transfer technique
is variable. Therefore, only animals that were positive for
exogenous expression of GK as determined by qRT-PCR (3x
SD of controls) were selected for further analysis (data not
shown). After selection, both GK-overexpressing groups had
identical protein levels and maximal activity (100mM glu-
cose) Figures 1(a)–1(b). These results are not in agreement
with the reported instability of liver GK protein in a PHHI-
GKA456V transgenic mouse [28] and the GKRP knock-out
model [37, 38], probably because of the lack of endogenous
transcriptional control in pGKA456V. Also, GKA456V activity at
5mM glucose was higher in liver extracts, as expected from
the kinetic changes associated with the mutation.
The GKA456V mutation resides on a hinge of the enzyme
responsible for the conformational changes associated with
GKRP interaction and allosteric activation. GKRP regulates
GK action in hepatocytes by retaining the enzyme in the
nucleus at low glucose concentrations and liberating GK
when insulin, high glucose levels, or fructose-1P is present
[26, 27]. We show here that GKA456V is predominantly
cytosolic in the liver of transfected animals, contrary to the
expected nuclear compartmentalization of wild-type GK.
In addition, GKA456V was not appropriately translocated to
the nucleus of diabetic primary hepatocytes in the presence
of excess GKRP (data not shown). Lack of GKRP binding
to GKA456V has been shown by Heredia et al. [6] in vitro
and inferred from the structural characterization of GK
bound to synthetic activators [12, 39]. Recent reports on the
P446L mutation in GKRP also suggest that a decrease in GK
inhibition results in increased GK activity, suggesting that
GK localizes to the cytosol [13].
An analysis of GK and GKA456V overexpression in well-
fed animals demonstrated small but significant changes
in glycemia, together with increased hepatic glucose
metabolism, as suggested by higher F2,6BP and glycogen
content, in the absence of alterations to lipid serum metabo-
lites. No changes were observed in enzymes or regulatory
proteins involved in gluconeogenesis in fed animals (data
not shown). These results are partially consistent with the
phenotype observed by Morral et al. [31, 33, 40], who used
a low dose of GK-expressing adenovirus (expressed largely
in periportal hepatocytes, [41, 42]) but diﬀer from those
obtained using high doses of adenovirus, indicating that
dose and/or zonal expression of GK influences the metabolic
impact of GK overexpression.
When animals were examined after a short fast (postab-
sorptive), marked diﬀerences were observed among groups.
(1) GK overexpression reduced glycemia ∼15%, con-
sistent with enhanced glucose metabolism in the liver, as
shown by increased G6P, F2,6BP, glycogen content, and
glycolytic and lipogenic enzymes together with higher serum
lactate, NEFA and TAG concentrations. Matsuzaka et al.
[43] have shown that a fed-to-fast transition in STZ-
diabetic mice results in increased gluconeogenic potential
and fatty acid oxidation in the liver, consistent with results
obtained in pControl-treated animals in the present study.
Conversely, pGK treatment resulted in reduced PEPCK and
PGC1α mRNA, supporting the view that GK overexpression
indirectly inhibits gluconeogenesis and fatty-acid oxidation.
Consistently, we measured higher NEFA and TAG serum
levels in the postabsorptive state although no changes in β-
hydroxybutyrate were observed. These results indicate that
enhanced glucose metabolism resulting fromGK overexpres-
sion had a small eﬀect on glycemia, possibly because pGK
dose was low.
(2) GKA456V overexpression led to a significant reduction
of serum glucose of ∼60% that was consistent with higher
glucose clearance on a glucose tolerance test in fasting,
healthy mice. Fasting hypoglycemia is also observed in
human carriers of the P446L GKRP mutation [14, 44].
GKA456V overexpression did not impact the concentration
of serum lipids whereas β-hydroxybutyrate was increased,
contrary to the dyslipidemia observed in GK overexpressing
animals in this and earlier studies, including human carriers
of the P446L GKRP mutation [14, 44]. Both kinetic and
regulatory issues might account for the observed diﬀerences.
Hepatic levels of F2,6BP and L-PK protein were increased
but other indicators (G6P, Fasn mRNA, ChREBP protein,
and mRNA and glycogen content) of glucose utilization were
lower than in GK-expressing livers. Importantly, glycogen
balance (fed-to-fast) was significantly lower in GKA456V-
expressing animals, indicating an important net loss of
glycogen. G6Pase expression was also higher in this group
of animals, providing an explanation for increased glycogen
loss observed in GKA456V-containing livers. The involvement
of G6Pase in the positive regulation of glycogenolysis has
been shown in several animal models overexpressing P36 or
P46 components of the G6Pase system, resulting in decreased
glycogen levels in the hepatocyte [45–48]. Moreover, a lack
of G6Pase system activity observed in glycogen storage
disease type 1a, or in a G6Pase KO promotes glycogen
accumulation [49]. Activation of the nonoxidative branch
of the pentose phosphate pathway, as a result of high
exogenous glucose, transiently upmodulates G6Pase mRNA
levels and stability in an insulin-independent manner [34,
35]. GKA456V-expressing livers showed higher G6PDH activ-
ity and GSH/GSSG ratio during the fed-to-fast transition
than control or GK groups (Figures 4(c)-4(d) and Table 1).
Increased G6Pase mRNA and protein in the presence of
GKA456V would suggest an induction of glucose cycling.
The physiological explanations for this futile pathway are
not completely understood. It is, however, clear that this
counter regulation shall have consequential eﬀects on glucose
homeostasis if persistent, as occurs in the GKA456V model.
All in all, the present data confirms that pGK overexpres-
sion in the liver results in relatively small changes in glycemia
but overt dislypidemia. The present model represents the
first attempt to overexpress pGK in perivenous hepatocytes,
and confirms previous observations using adenovirus [29].
In contrast to the work of Scott et al. [50] and Morral
et al. [40], GK overexpression in perivenous hepatocytes
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does not significantly aﬀect Glc6Pase expression, suggesting
that zonation is an important experimental variable not
suﬃciently addressed to date in the field. In addition, we have
demonstrated that GKA456V overexpression reduces blood
glucose to a great extent, probably due to its capacity to
induce Glc6Pase.
We conclude that impaired GKRP regulation and
GKA456V altered kinetics greatly influence liver metabolism,
in line with results obtained in humans with a mutant GKRP.
Besides, it suggests that activating GK exclusively in the
liver could be a feasible strategy for diabetes, widening the
scope for GKA research. Similar conclusions, based on its
potent induction of glucose clearance by the liver, have been
obtained after liver-specific GK activation in chicken in a
recent study by Rideau et al. [51]. Studies on animal models
of type 2 diabetes are under way in our laboratory in order
to evaluate the metabolic impact in the context of insulin
resistance and obesity.
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